搜索
Search
这是描述信息

中文(wén)

News Center

Homepage
/
Milestones
2022
2022
2022
2022-11-29
In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.
View details
In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.
2021
2021
2021
2022-04-22
The Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed in collaboration by Institute of Biophysics in the Chinese Academy of Sciences and Livzon Mabpharm Inc., a subsidiary of Livzon Pharmaceutical Group, has obtained the clinical approval from the National Medical Products Administration, and is currently conducting multi-reginal Phase III clinical trials.
View details
The Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed in collaboration by Institute of Biophysics in the Chinese Academy of Sciences and Livzon Mabpharm Inc., a subsidiary of Livzon Pharmaceutical Group, has obtained the clinical approval from the National Medical Products Administration, and is currently conducting multi-reginal Phase III clinical trials.
2020
2020
2020
2021-11-16
Corporate culture reform with mission of "Patient Quality of Life Comes First" and vision of "Be the Pharmaceutical Industry Leader"
View details
Corporate culture reform with mission of "Patient Quality of Life Comes First" and vision of "Be the Pharmaceutical Industry Leader"
2016
2016
2021-11-16
Livzon new industrial park completed
View details
Livzon new industrial park completed
2014
2014
2014
2021-11-16
B-share stock transfer to H-share stock
View details
B-share stock transfer to H-share stock
2010
2010
2010
2021-11-16
Focused on the field of biological products, and established monoclonal antibody company
View details
Focused on the field of biological products, and established monoclonal antibody company
2008
2008
2008
2021-11-16
Foundations laid for Livzon new industrial park, which is a domestic leading, world-class modern pharmaceutical production base
View details
Foundations laid for Livzon new industrial park, which is a domestic leading, world-class modern pharmaceutical production base
2002
2002
2002
2021-11-16
Completed shareholding system reform, and became the first listed company both in A-share and B-share stock markets in domestic pharmaceutical industry
View details
Completed shareholding system reform, and became the first listed company both in A-share and B-share stock markets in domestic pharmaceutical industry
Previous page
1
2

Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China    Tel： 0756-8135888    

©2021 Livzon  Support：300.cn

Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China  

©2021 Livzon   

 Support：300.cn